Introducing SNAP: Spontaneous Nanoliposome Antigen Particles
POP Biotechnologies is focused on utilizing the versatile SNAP platform to discover, validate, and commercialize innovative vaccines ands immunotherapies for the treatment and prevention of infectious disease and chronic diseases including cancer.
The SNAP Platform for Advancing Vaccine Treatments
The POP BIO SNAP approach is a game-changer in vaccine development. By incubating His-tagged antigens with SNAP-liposomes, we can seamlessly and stably insert the antigens into the bilayer and create a His-tag membrane anchor. This innovative technology addresses the functional and practical limitations faced by traditional vaccine development methods, paving the way for more effective and efficient vaccines.
How the SNAP Approach Works so Effectively
1
2
3
The SNAP Approach -
Form Multivalent Particles with Ease
Protein & Virus-Like-Particle Vaccines
(depends on platform)
Transforming Vaccine Development with Innovative Nanoparticles
Recombinant proteins and peptides offer a safe and simple method for vaccine production. However, they often fail to produce a robust immune response. The SNAP platform addresses this limitation by providing a novel nanoparticle platform that simplifies vaccine adjuvants.
Simple and Efficient Antigen Insertion Process
The SNAP approach involves incubating His-tagged antigens with SNAP-liposomes, resulting in efficient antigen insertion.
Streamlined Vaccine Development and Manufacturing
The SNAP platform simplifies the vaccine development and manufacturing process, saving time and resources.
Enhanced Immune Response and Protection
By improving immune response, the SNAP platform offers enhanced protection against diseases.
The Power of Vaccines with SNAP
A Clear Path Toward Human Testing
The CoPoP vaccine, manufactured by POP BIO and produced at a 2.5M dose scale under GMP, includes other components that are also obtainable under GMP.
A CoPoP GLP toxicity report is accessible, and CoPoP is a component of EuCorVac-19, which underwent testing in a 280-person phase 1/2 trial. Additionally, there is a testing framework for human epitopes.
Selected Publications
Below is our carefully curated shortlist of more than 20 peer-reviewed publications that have been rigorously vetted by experts in the field and deemed to be of the highest quality.